<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Evofem Biosciences Inc — News on 6ix</title>
<link>https://6ix.com/company/evofem-biosciences-inc</link>
<description>Latest news and press releases for Evofem Biosciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Mon, 27 Apr 2026 13:25:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/evofem-biosciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835651b78dffbe2df0eff0b.webp</url>
<title>Evofem Biosciences Inc</title>
<link>https://6ix.com/company/evofem-biosciences-inc</link>
</image>
<item>
<title>Evofem Announces Exclusive Agreement for the Distribution and Commercialization of SOLOSEC in Sub-Saharan Africa</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-announces-exclusive-agreement-for-the-distribution-and-commercialization-of-solosec-in-sub-saharan-africa</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-announces-exclusive-agreement-for-the-distribution-and-commercialization-of-solosec-in-sub-saharan-africa</guid>
<pubDate>Mon, 27 Apr 2026 13:25:00 GMT</pubDate>
<description>SAN DIEGO, April 27, 2026--Women’s health innovator Evofem Biosciences, Inc. (OTCID: EVFM) (Evofem or the Company) today announced that it has entered into an exclusive Distribution Agreement with Clovis Davis Pharmaceuticals, LLC, a distributor of pharmaceutical and related products (Clovis Davis), to commercialize SOLOSEC® (secnidazole) 2g oral granules in sub-Saharan Africa (the Territory).</description>
</item>
<item>
<title>Evofem Reports Fifth Consecutive Year of Net Sales Growth</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-fifth-consecutive-year-of-net-sales-growth-22</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-fifth-consecutive-year-of-net-sales-growth-22</guid>
<pubDate>Wed, 11 Mar 2026 20:05:00 GMT</pubDate>
<description>Evofem Reports Fifth Consecutive Year of Net Sales Growth.</description>
</item>
<item>
<title>Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-calls-for-a-ground-up-reset-of-womens-health-at-fierce-jpm-week-2026-1</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-calls-for-a-ground-up-reset-of-womens-health-at-fierce-jpm-week-2026-1</guid>
<pubDate>Fri, 23 Jan 2026 14:25:00 GMT</pubDate>
<description>Evofem CEO Saundra Pelletier Calls for a “Ground-Up Reset” of Women’s Health at Fierce JPM Week 2026.</description>
</item>
<item>
<title>Evofem CEO Saundra Pelletier Calls for a "Ground-Up Reset" of Women’s Health at Fierce JPM Week 2026</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-calls-for-a-ground-up-reset-of-womens-health-at-fierce-jpm-week-2026</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-calls-for-a-ground-up-reset-of-womens-health-at-fierce-jpm-week-2026</guid>
<pubDate>Fri, 23 Jan 2026 14:25:00 GMT</pubDate>
<description>SAN DIEGO, January 23, 2026--Evofem CEO's fiery keynote address at Fierce JPM Week 2026 calls for "Ground-Up Reset" of Women’s Health. Replay now live at fiercejpmweek.com.</description>
</item>
<item>
<title>Evofem Expands "Say Vagina" Campaign With Launch of Say Vagina Store</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-expands-say-vagina-campaign-with-launch-of-say-vagina-store</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-expands-say-vagina-campaign-with-launch-of-say-vagina-store</guid>
<pubDate>Wed, 21 Jan 2026 16:00:00 GMT</pubDate>
<description>SAN DIEGO, January 21, 2026--Evofem launched SayVaginaStore.com, expanding its 'Say Vagina' campaign addressing widespread censorship of female anatomical terms in the media.</description>
</item>
<item>
<title>Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-expands-say-vagina-campaign-with-launch-of-say-vagina-store-1</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-expands-say-vagina-campaign-with-launch-of-say-vagina-store-1</guid>
<pubDate>Wed, 21 Jan 2026 16:00:00 GMT</pubDate>
<description>Evofem Expands “Say Vagina” Campaign With Launch of Say Vagina Store.</description>
</item>
<item>
<title>Favorable Pricing Certificates Issued for Evofem's PHEXX by Emirates Drug Establishment are Launching Step for Commercialization in UAE</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/favorable-pricing-certificates-issued-for-evofems-phexx-by-emirates-drug-establishment-are-launching-step-for-commercialization-in-uae</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/favorable-pricing-certificates-issued-for-evofems-phexx-by-emirates-drug-establishment-are-launching-step-for-commercialization-in-uae</guid>
<pubDate>Fri, 21 Nov 2025 14:25:00 GMT</pubDate>
<description>Women's health innovator Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) announced today that the Emirates Drug Establishment (EDE) has issued favorable pricing certificates for PHEXX® (lactic acid, citric acid, potassium bitartrate), which is a preliminary administrative step toward regulatory approval in the United Arab Emirates (UAE).</description>
</item>
<item>
<title>Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-financial-results-for-third-quarter-of-2025-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-financial-results-for-third-quarter-of-2025-provides-business-update</guid>
<pubDate>Thu, 13 Nov 2025 21:05:00 GMT</pubDate>
<description>Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and nine-month periods ended September 30, 2025 and provided a business update.</description>
</item>
<item>
<title>Evofem Announces Voting Results from Special Meeting of Stockholders</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-announces-voting-results-from-special-meeting-of-stockholders</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-announces-voting-results-from-special-meeting-of-stockholders</guid>
<pubDate>Mon, 20 Oct 2025 20:18:00 GMT</pubDate>
<description>Evofem Biosciences, Inc. (OTCID: EVFM) ("Evofem" or the "Company"), today announced that at a Special Meeting of Stockholders held this morning, its stockholders did not approve the proposal to adopt the Amended and Restated Merger Agreement dated July 12, 2024, as subsequently amended (the "Merger Agreement"), between the Company, Aditxt, Inc. (NASDAQ: ADTX), and Adifem, Inc., a wholly owned subsidiary of Aditxt, under which Aditxt intended to acquire Evofem. As a result, Evofem has exercised i</description>
</item>
<item>
<title>Evofem's SOLOSEC Submitted for Marketing Approval in United Arab Emirates</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofems-solosec-submitted-for-marketing-approval-in-united-arab-emirates</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofems-solosec-submitted-for-marketing-approval-in-united-arab-emirates</guid>
<pubDate>Wed, 01 Oct 2025 12:47:00 GMT</pubDate>
<description>Women's health innovator Evofem Biosciences, Inc. (Evofem, or the Company) (OTCID: EVFM) announced today that its licensee for the Middle East and North Africa (MENA), private Emirati health care company Pharma 1, has filed an application with the United Arab Emirates (UAE) Ministry of Health and Prevention (MOHAP) seeking approval to commercialize SOLOSEC® (secnidazole) 2 g oral granules, Evofem's FDA-approved single-dose oral treatment for two common sexual health conditions.</description>
</item>
<item>
<title>Evofem Biosciences Honors World Contraception Day</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-biosciences-honors-world-contraception-day</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-biosciences-honors-world-contraception-day</guid>
<pubDate>Fri, 26 Sep 2025 12:15:00 GMT</pubDate>
<description>On World Contraception Day, Evofem Biosciences, Inc. ("Evofem" or "the Company") (OTCID: EVFM) honors the millions of people worldwide who rely on contraception not only to prevent pregnancy, but to take control of their health, their futures, and their freedom. Access to contraception remains uneven across countries and communities; the need for more education, innovation, and de-stigmatization has never been greater.</description>
</item>
<item>
<title>Evofem's "Say Vagina" Campaign Generates More than 2.5 Million Views Across Social Media Platforms</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofems-say-vagina-campaign-generates-more-than-25-million-views-across-social-media-platforms</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofems-say-vagina-campaign-generates-more-than-25-million-views-across-social-media-platforms</guid>
<pubDate>Thu, 11 Sep 2025 13:18:00 GMT</pubDate>
<description>Evofem Biosciences, Inc. (Evofem) (OTCID: EVFM) today announced the conclusion and exciting impact of its groundbreaking August 2025 "Say Vagina" campaign, which aimed to normalize the use of clinical anatomical language and to combat the widespread censorship of essential medical terminology.</description>
</item>
<item>
<title>Evofem Anticipates Approval of Merger with Aditxt at Upcoming Stockholder Meeting</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-anticipates-approval-of-merger-with-aditxt-at-upcoming-stockholder-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-anticipates-approval-of-merger-with-aditxt-at-upcoming-stockholder-meeting</guid>
<pubDate>Tue, 09 Sep 2025 13:28:00 GMT</pubDate>
<description>In an update to stockholders today, Evofem Biosciences, Inc. ("Evofem" or the "Company") (OTCID: EVFM) anticipates the approval of the transactions (the "Merger") contemplated by the Amended and Restated Merger Agreement dated as of July 12, 2024, as amended, (collectively, the "Merger Agreement"), with Aditxt, Inc. (Nasdaq: ADTX) and Adifem, Inc., a wholly-owned subsidiary of Aditxt, at the Company's Special Meeting of Stockholders (the "Special Meeting") to be held on September 26, 2025.</description>
</item>
<item>
<title>Illinois Pharmacists Can Prescribe PHEXXI Starting January 2026 Under Newly-passed Law</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/illinois-pharmacists-can-prescribe-phexxi-starting-january-2026-under-newly-passed-law</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/illinois-pharmacists-can-prescribe-phexxi-starting-january-2026-under-newly-passed-law</guid>
<pubDate>Thu, 21 Aug 2025 12:56:00 GMT</pubDate>
<description>On August 15, 2025, Illinois enacted House Bill 3489, a measure designed to broaden access to contraception for its residents. This legislation permits pharmacists to prescribe a wider array of contraceptive options, including PHEXXI® (lactic acid, citric acid, and potassium bitartrate) , the hormone-free on-demand contraceptive vaginal gel from Evofem Biosciences (OTCID: EVFM). The law is slated to take effect on January 1, 2026.</description>
</item>
<item>
<title>FDA Orange Book Lists New U.S. Patent for SOLOSEC, Evofem Biosciences' "One and Done" Oral Treatment for Bacterial Vaginosis and Trichomoniasis</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/fda-orange-book-lists-new-us-patent-for-solosec-evofem-biosciences-one-and-done-oral-treatment-for-bacterial-vaginosis-and-trichomoniasis</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/fda-orange-book-lists-new-us-patent-for-solosec-evofem-biosciences-one-and-done-oral-treatment-for-bacterial-vaginosis-and-trichomoniasis</guid>
<pubDate>Tue, 19 Aug 2025 13:39:00 GMT</pubDate>
<description>Evofem Biosciences, Inc. (OTCID: EVFM) today announced that a newly-issued U.S. patent which covers SOLOSEC® (secnidazole) 2 g oral granules and one of its labeled indications is now listed in the U.S. Food and Drug Administration (FDA) publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book.</description>
</item>
<item>
<title>Evofem Reports Positive Financial Results for Second Quarter of 2025, Provides Business Update</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-positive-financial-results-for-second-quarter-of-2025-provides-business-update</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-reports-positive-financial-results-for-second-quarter-of-2025-provides-business-update</guid>
<pubDate>Thu, 14 Aug 2025 12:46:00 GMT</pubDate>
<description>Women's health innovator Evofem Biosciences, Inc. (Evofem or the Company) (OTCID: EVFM), today announced financial results for the three- and six-month periods ended June 30, 2025 and provided a business update. Notable developments since April 1st include:</description>
</item>
<item>
<title>Evofem CEO Saundra Pelletier Honored with Trailblazing Female Founders Award at STIMULATE Conference</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-honored-with-trailblazing-female-founders-award-at-stimulate-conference</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/evofem-ceo-saundra-pelletier-honored-with-trailblazing-female-founders-award-at-stimulate-conference</guid>
<pubDate>Tue, 05 Aug 2025 12:46:00 GMT</pubDate>
<description>Evofem Biosciences, Inc. (OTCID: EVFM) is proud to announce that its CEO, Saundra Pelletier, will be honored with the Trailblazing Female Founders Award at the 2025 STIMULATE Conference, the premier U.S. sexual wellness industry event. The award will be presented today, August 5, 2025, during the conference held in Nashville, Tennessee.</description>
</item>
<item>
<title>Phexxi -- A Non‑Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/phexxi-a-nonhormonal-birth-control-brand-goes-viral-with-microfeminism-on-tiktok-featured-by-buzzfeed-and-scary-mommy</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/phexxi-a-nonhormonal-birth-control-brand-goes-viral-with-microfeminism-on-tiktok-featured-by-buzzfeed-and-scary-mommy</guid>
<pubDate>Tue, 15 Jul 2025 13:12:00 GMT</pubDate>
<description>One viral TikTok, 10 million+ views, and a flood of fearless, funny, and unfiltered replies later, a non-hormonal birth control brand — PHEXXI — has found itself at the center of a national conversation on microfeminism. It all started with one unapologetic prompt:</description>
</item>
<item>
<title>Phexxi -- A Non-Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/phexxi-a-non-hormonal-birth-control-brand-goes-viral-with-microfeminism-on-tiktok-featured-by-buzzfeed-and-scary-mommy</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/phexxi-a-non-hormonal-birth-control-brand-goes-viral-with-microfeminism-on-tiktok-featured-by-buzzfeed-and-scary-mommy</guid>
<pubDate>Tue, 15 Jul 2025 13:12:00 GMT</pubDate>
<description>Phexxi -- A Non-Hormonal Birth Control Brand -- Goes Viral with Microfeminism on TikTok, Featured by BuzzFeed and Scary Mommy.</description>
</item>
<item>
<title>Aditxt to Present at Wall Street Reporter’s NEXT SUPER STOCK Livestream Today June 26, 2025, at 1 p.m. ET</title>
<link>https://6ix.com/company/evofem-biosciences-inc/news/aditxt-to-present-at-wall-street-reporters-next-super-stock-livestream-today-june-26-2025-at-1-pm-et</link>
<guid isPermaLink="true">https://6ix.com/company/evofem-biosciences-inc/news/aditxt-to-present-at-wall-street-reporters-next-super-stock-livestream-today-june-26-2025-at-1-pm-et</guid>
<pubDate>Thu, 26 Jun 2025 12:15:00 GMT</pubDate>
<description>MOUNTAIN VIEW, Calif., June 26, 2025--Aditxt, Inc. (NASDAQ: ADTX) ("Aditxt" or the "Company"), a social innovation platform accelerating promising health innovations, is pleased to announce that Co-founder and CEO Amro Albanna will be presenting at Wall Street Reporter’s NEXT SUPER STOCK livestream event on June 26, 2025 at 1:00 p.m. ET.</description>
</item>
</channel>
</rss>